Hanmi Pharmaceutical secureda patent for an inhalation asthma and COPD treatment ‘Fluterol’
Hanmi Pharmaceutical (executive director Kwan-soon Lee)made a public announcement aboutacquisition of domestic patent on the self-developed inhalation asthma and COPD treatment ‘Fluterol’.
Fluterol is a drug installedin a specially designed capsule to inhale; the technology maximized drug effect...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
